SCI-110 in the Treatment of Tourette Syndrome
A legfontosabb adatok
- Ki végzi
- Neurothera Labs Inc.
- Hol
- Tel Aviv (Izrael)A helyszín megnézéseMég 2 másik országban, 2 helyszínen
- Azonosító
- Állapot
- Toborzás még nem indult
- Fázis
- 2. fázis
- Résztvevők
- 164 fő, tervezett
- Kezdés
- 2026. jún.
- Várható befejezés
- 2028. febr.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- SCI-110
- Placebo
- A regiszteradat frissítve
- 2026. április 21.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with Tourette syndrome to test the cannabis-based medicine SCI-110 against a placebo (dummy pill).
- Életkor
- 18 to 65 years
- Nem
- Men and women
- A betegség stádiuma
- Tourette syndrome diagnosed by DSM-5 criteria. Total tic score on the YGTSS-R above 14. CGI-S severity score of 4 or more.
- Korábbi kezelés
- Medicines for tics or other conditions, and deep brain stimulation settings, must be stable for at least 6 weeks and stay stable. No cannabis or cannabinoid-based medicine in the 30 days before entry. No ongoing behavioural therapy for tics.
- Biomarker vagy leletérték
- Negative THC urine test at the start. Women who could become pregnant need a negative pregnancy test.
A részvétel fő kizáró okai
- Unstable OCD, ADHD, depression or anxiety, or severe psychiatric illness such as psychosis or bipolar disorder
- History of schizophrenia, seizures, cannabis dependence, or current substance abuse
- Other tic disorders or other significant neurological disorders
- Severe heart, liver or kidney disease, or known HIV, hepatitis B or hepatitis C
- Pregnancy, breastfeeding, active suicidal thoughts or a past suicide attempt
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- Tourette syndrome according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
- Male and female subjects with an age between ≥18 and ≤65 years
- Total tic score (TTS) of the revised Yale Global Tic Severity Scale (YGTSS-R) \>14
- Clinical Global Impression-Severity Score (CGI-S) ≥4
- Medication (and stimulation parameters for deep brain stimulation) for tics and comorbidities must be on a stable dose for at least 6 weeks before entering the study and subject must consent to maintain the stable dose during the study
- Signed written informed consent and willingness to comply with treatment and follow-up procedures
- Subjects capable of understanding the investigational nature, potential risks and benefits of the clinical study
- Women of child-bearing potential must have a negative pregnancy test (e.g., urine human chorionic gonadotropin [hCG]) before first treatment with study medication. They must practice a highly effective, reliable and medically approved contraceptive regimen during the study (e.g., theoretical failure rate less than 1% per year as when used consistently and correctly), which include oral or parenteral or implanted hormonal contraception, vaginal ring releasing hormonal contraception (e.g., Nuvaring), intrauterine device or intrauterine system. Women without childbearing potential may enter this study. Women without childbearing potential defined as follows:; at least 6 weeks after surgical sterilization by bilateral tubal ligation or bilateral oophorectomy or; hysterectomy or uterine agenesis or; ≥ 50 years and in postmenopausal state ≥ 1 year or; \< 50 years and in postmenopausal state ≥ 1 year with urine FSH \> 40 IU/l and urine oestrogen \< 30 ng/l, or serum follicle stimulating hormone (FSH) in the post-menopausal range or a negative oestrogen test
- Male subjects must be willing to use a condom with sexual partners during this study and for a period of three months following the last administration of study medication until the follow-up visit. Male subjects must be willing to abstain from sperm donation for 3 months after the completion of this study
Ki nem vehet részt
- Concomitant medications have to be on stable dose since at least 6 weeks before entering the study and must be well tolerated at baseline without causing dizziness, confusion, sedation, or somnolence)
- Use of cannabis or cannabinoid-based medicine (CBM) in the 30-day period prior to study entry and/or positive delta-9-tetrahydrocannabinol (THC) urine test at baseline
- Subjects who received any investigational medication or used any investigational device within 30 days prior to the first dose of study medication or is actively participating in any investigational drug or device study, or is scheduled to receive an investigational drug or to use an investigational device during the course of the study
- Comorbid obsessive-compulsive disorder (OCD), attention deficit/hyperactivity disorder (ADHD), depression, and anxiety disorder when unstable or in need of an initial adjustment for a therapy-according to the investigator's judgment
- Presence of severe psychiatric conditions such as developmental disability, psychotic illness and bipolar disorder- according to the investigator's judgment
- History of schizophrenia, seizure, psychotic, severe personality, or pervasive developmental disorder
- History of cannabis dependence
- Secondary and other chronic tic disorders or other significant neurological disorders
- Known severe cardiac diseases, known severe cardiovascular diseases, known positivity for human immunodeficiency virus (HIV), hepatitis C, hepatitis B, or other severe hepatic and renal disorders by history
- Subjects with a known allergy, hypersensitivity, or intolerance to the active substances and ingredients of study medication (e.g., cannabis, cannabinoids, or sesame oil)
- Any condition, which in the opinion of the investigator, would interfere with the evaluation of the study product or poses a health risk to the subject
- Ongoing behavioural treatment for tics
- Current clinical diagnosis of substance abuse or dependence
- Positive urine ß-HCG pregnancy test
- Pregnant or breast-feeding women
- Subjects who are employees of the sponsor or employees or close relatives of the investigator
- Subjects with active suicidal ideation and behaviour (SI/B) according to the Columbia-Suicide Severity Rating Scale (C-SSRS) and/or subjects that have attempted suicide in the past
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 65 év között vagy?
Helyszínek itt: Izrael
Még 2 másik országban, 2 helyszínen
- Neurological Institute, Tel Aviv Sourasky Medical CenterTel Aviv, IzraelContact: Tanya Gurevich, PhD. MDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
To evaluate the efficacy, safety and tolerability of the cannabinoid-based medication SCI-110 compared to placebo in subjects with Tourette syndrome.
A vizsgálat 2 csoportja
- SCI-110A vizsgált kezelés
Cannabinoid-based medication consisting of Dronabinol and PEA
- DronabinolPlacebo, összehasonlításként
Placebo matched in taste, odour and appearance to SCI-110
Kezelés: Placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Evaluate the Efficacy, Safety and Tolerability of Daily Oral SCI-110 in Treating Adults With Tourette Syndrome.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT05126888: ki vehet részt
- A regiszteradat frissítve
- 2026. április 21.